Dr. Tesi has been Chairman since the formation of the Company in September 2015. Since December 2016, Dr. Tesi has been a Director of Savant HWP, an addiction medicine company. From November 2011 to May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development-stage biotech company formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases. From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech company in Bergamo, Italy focused on products to treat patients with hematologic malignancy. From June 2007 to September 2010, Dr. Tesi was CEO and President of Coronado Biosciences, a company he founded. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician since 1982 and Fellow of the American College of Surgery since 1991.

Dr. Tesi’s significant experience with our licensed technology and his experience as a transplant surgeon, entrepreneur, investor and director of start-up biopharmaceutical companies were instrumental in his selection as a member of the Board of Directors.

Mr. Moss has been CFO since the formation of the Company in September 2015. Mr. Moss has founded, funded and taken public various companies in a variety of industries since 1995. Mr. Moss was a founding investor in Reliant Service Group LLC, which was acquired in 2015 by a leading private equity firm. Mr. Moss previously served as Managing Director, Corporate Finance for a New York-based securities firm, where he advised companies on corporate strategy, financings and business development. Prior to that, he served as Managing Partner at a Seattle-based venture capital firm. Mr. Moss holds an MBA from Rice University and a BA in Economics from the University of California, San Diego.

Prof. Lowdell has been a Chief Scientific Officer and Chief Manufacturing Officer since the formation of the Company in September 2015. Prof. Lowdell is Professor of Cell and Tissue Therapy at University College London, where he has led a translational immunotherapy group since 1994. Since February 2009, Prof. Lowdell has also been Director of Cellular Therapy at the Royal Free London NHS Foundation Trust. He received his PhD in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Dr. Barnum is the Head of Neuroscience at INmune Bio, Inc. Dr. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academia and industry, including Emory University, FPRT Bio., SonosBio, and most recently Takeda Pharmaceuticals. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Dr. Barnum has been working with XPro1595 for more than a decade, first at Emory University with Dr. Malú Tansey and subsequently as a consultant for FPRT Bio., Inc. and INmune Bio, before joining INmune Bio full time in 2018. Dr. Barnum’s research has been supported by NIH, The Michael J Fox Foundation, and the Alzheimer’s Association. He received his PhD in Neuroscience from Binghamton University.

Mr. Schoonover is our in-house counsel, primarily focused on developing intellectual property rights for the Company, as well as managing various licenses and other agreements. Mr. Schoonover has over ten years of experience building and monetizing intellectual property portfolios. His experience also includes multiple transactions, including a recent nine-figure acquisition of a portfolio containing over 230 patent matters which Mr. Schoonover drafted and prosecuted. He received a JD from Western Sierra Law School and a BS in Chemical Physics from San Diego State University. Mr. Schoonover is a member of the State Bar of California and is licensed to practice before the United States Patent & Trademark Office, the Southern District of California and the 9th Circuit Court of Appeals.

Ms. Lehner is the Vice President of Clinical Operations at INmune Bio. She has spent over 22 years in the pharmaceutical industry both as an employee and a consultant working across pharma, biotech and contract research organizations. In her last position, Ms. Lehner oversaw a $400 million dollar book of business for a long-term strategic partnership. Ms. Lehner holds an MS from the Temple University School of Pharmacy and a BA in Neuroscience from the University of Delaware and has been a certified PMP since 2011.

Dr. Tesi has been Chairman since the formation of the Company in September 2015. Since December 2016, Dr. Tesi has been a Director of Savant HWP, an addiction medicine company. From November 2011 to May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development-stage biotech company formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases. From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech company in Bergamo, Italy focused on products to treat patients with hematologic malignancy. From June 2007 to September 2010, Dr. Tesi was CEO and President of Coronado Biosciences, a company he founded. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician since 1982 and Fellow of the American College of Surgery since 1991.

Dr. Tesi’s significant experience with our licensed technology and his experience as a transplant surgeon, entrepreneur, investor and director of start-up biopharmaceutical companies were instrumental in his selection as a member of the Board of Directors.

J. Kelly Ganjei is the CEO and President of AmplifyBio, LLC, a contract research organization focused on helping advanced therapy clients navigate the concept to commercial journey. Mr. Ganjei was brought in to lead the spin-out of AmplifyBio from Battelle in mid-2021.

Before AmplifyBio, Mr. Ganjei was the Chief Executive Officer and Chairman of the Board of Cognate BioServices, a CDMO focused on the cell and gene therapy fields. Mr. Ganjei has nearly 30 years of experience within the advanced therapy business, venture capital, and IT sectors.

Previously, Mr. Ganjei was involved in many start-up companies with leadership roles, including but not limited to, Remegenix, TissueGene, LabVantage, and Biognosis. In these roles, he was responsible for spearheading the commercialization of innovative approaches to treating traumatic brain injury and Alzheimer’s disease, an allogenic cell-mediated gene therapy with complex development and regulatory pathways and developing the global informatics infrastructure for the company and its affiliates. Mr. Ganjei started his career working under Ron Schwartz, Luciano D’Adamio, and others in the Lab of Cellular and Molecular Immunology at the NIAID within the NIH.

Mr. Ganjei has published numerous scientific, peer-reviewed papers and has been a guest speaker and presenter at various business forums. Mr. Ganjei received his B.S. in Microbiology from the University of Maryland College Park in 1995. Mr. Ganjei has significant biotechnology operational experience and pre-clinical, clinical, and commercial drug development and manufacturing knowledge.

Mr. Juda has been a director since March 2018. Mr. Juda is Manager and co-founder of Fossick Capital, a technology-focused hedge fund. Mr. Juda co-founded The Juda Group, Inc., an institutional capital markets focused broker-dealer division of CCM, where he served as Chief Executive Officer from 2012 to 2016. Before that, Mr. Juda was at SMH Capital from 2002 to 2011, serving as a Managing Director in the Investment Banking Group and Chief Operating Officer of The Juda Group subsidiary. From 2000 to 2002, Mr. Juda was an institutional sales-trader for Sutro & Co. From 1997 to 2000, Mr. Juda practiced corporate and securities law at Buchalter Nemer LLP. Mr. Juda received his bachelor degree from the University of Southern California and his juris doctor from the University of Pepperdine School Of Law. Mr. Juda is a member of the State Bar of California.

Mr. Schroeder has been a director since December, 2016 Mr. Schroeder has more than 35 years of clinical and academic industry experience in global drug and device development programs. He is CEO of CTI Clinical Trial and Consulting Services, a multi-national research firm with locations in North America, Europe, Latin America and Asia-Pacific. The firm has supported more than 100 drug and device approvals, and works on behalf of approximately 120 global pharmaceutical and biotechnology companies. Prior to founding CTI, Mr. Schroeder was a faculty member of the University of Cincinnati College of Medicine. He previously served as Executive Vice President of Clinical Development at SangStat Medical Corporation, a firm he co-founded. Mr. Schroeder is a board member for more than a dozen corporate and non-profit organizations. He was named as EY Entrepreneur of the Year in 2015 and was recognized as Top Leader by the Enquirer Media in 2016.

Ms. Allen is the CEO and founder of Allen & Associates. For the past twenty years she has been devoted to venture capital and corporate finance representing both investors and companies, primarily in the small to mid-cap arena. Her focus has been on building asset value through acquisition and internal growth funded by institutional investment groups. In this capacity, Ms. Allen was a Managing Director of Elite Capital, Inc., a Southern California Venture Capital Firm. She has also served as principal at Allen/Brenner, Inc., an Orange County based money and cash management firm. Ms. Allen was responsible for building its portfolio under management to approximately $1.0 billion at which time she divested the client base to a major Wall Street investment banking firm. During these years Ms. Allen was a founder and served as CFO and Director of The Movie Group, (AMX) the originating company which is today Lionsgate Entertainment (NYSE). She has more than 25 years with mergers and acquisitions, corporate finance and CFO and CEO experience. Ms. Allen was a Chief Financial Officer and Corporate Development Officer for W.R. Grace & Co. (NYSE) and was part of the founding group of Ruby Tuesday, Inc., (NYSE) a national restaurant chain. She relocated to join Taco Bell, Inc. as the Company's Chief Financial Officer where she structured and facilitated the acquisition of Taco Bell, Inc. by PepsiCo, Inc. Her expertise in the corporate world comes from both the operational sector and investment arena, which gives her unique insight and advantage. Ms. Allen received a Bachelors, Finance and Accounting from Haslam College of Business at the University of Tennessee in finance and accounting. She has been a speaker for Strategic Research Institute, Inc. magazine, the National Restaurant Association, the California Restaurant Association, the American Institute of Certified Public Accountants and the Los Angeles Venture Association (LAVA). She is active in numerous civic and political organizations and sits on the Board of Directors of several public and private companies and philanthropic organizations. She currently serves as the chairperson of the Audit Committee and as an independent director of Ark Restaurants Corp. (NASDAQ), an owner and operator of 20 restaurants and bars, 21 fast food concepts, and catering operations primarily in New York City; Florida; Washington, DC; and Las Vegas, NV.